NDC product
Doxorubicin Hydrochloride Liposome
NDC 25021-263 · Sagent Pharmaceuticals
Key facts
| Product NDC | 25021-263 |
|---|---|
| Proprietary name | Doxorubicin Hydrochloride Liposome |
| Nonproprietary name | Doxorubicin Hydrochloride |
| Substances | DOXORUBICIN HYDROCHLORIDE |
| Dosage form | INJECTION, SUSPENSION, LIPOSOMAL |
| Route | INTRAVENOUS |
| Labeler | Sagent Pharmaceuticals |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA219881 |
| Pharmacologic classes | Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA] |
| Marketing start | Mar 1, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: